Conatus liver drug shows positive results in mid-stage trial
{{#rendered}} {{/rendered}}
Conatus Pharmaceuticals Inc said its experimental drug, emricasan, succeeded in reducing the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial.
Data showed a statistically significant reduction in the protein fragment, caspase-cleaved cytokeratin 18 (cCK18), when compared with a placebo in the overall patient population.
cCK18, an important marker of liver cell death, is elevated in patients with advanced liver disease and cirrhosis, the company said.
{{#rendered}} {{/rendered}}
(Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)